Enfortumab vedotin (EV) is an antibody-drug conjugate approved for the treatment of
refractory advanced urothelial cancer. Cutaneous toxicity is well described but has not been …

Background Locally advanced or metastatic urothelial carcinoma is generally incurable and
has scarce treatment options, especially for cisplatin-ineligible patients previously treated …

4504 Background: Patients (pts) with mUC are in need of novel therapies. Enfortumab
vedotin (EV) is an antibody–drug conjugate that delivers a microtubule-disrupting agent to …

The antibody-drug conjugate enfortumab vedotin is a fully humanized monoclonal antibody
targeting Nectin-4 linked to a microtubule-disrupting agent, monomethyl auristatin E, via a …

Following the recent FDA Accelerated Approval of enfortumab vedotin (EV) plus
pembrolizumab for patients with advanced-stage urothelial carcinoma who are cisplatin …

Simple Summary Enfortumab vedotin, a targeted therapy for advanced urothelial carcinoma,
has shown efficacy, especially in those treated with platinum-based chemotherapy and …

4505 Background: Locally advanced or metastatic urothelial cancer (la/mUC) remains a
lethal disease with limited treatment options for patients (pts) who progress on or after …

Abstract Purpose of Review Urothelial carcinoma (UC) is a common malignancy with an
urgent need for more effective and less toxic treatment strategies. Antibody-drug conjugate …

Background: Antibody-drug conjugates have recently been introduced as a treatment for
advanced urothelial carcinoma. The EV-301 study demonstrated that enfortumab vedotin …

TPS589 Background: Platinum-based chemotherapy is standard first line (1L) therapy for
aUC. Maintenance therapy may be offered for patients (pts) who do not progress on 1L …